panaloko login register philippines

To play Maria Callas, Angelina Jolie had to lean how to breathe againDoorDash is adding new grocers to its list of supermarket delivery partners. The delivery platform will be working with five new grocers, according to a Monday (Nov. 25) press release . The aggregator has already added several supermarket chains this year, including Wegmans and all of Ahold Delhaize ’s American banners. “It has been a monumental year for DoorDash’s grocery business with many beloved grocers — from the nation’s largest supermarket chains to neighborhood favorites — joining the platform,” Fuad Hannon , vice president of new verticals at DoorDash, said in the release. “On-demand delivery continues to play an essential role in consumers’ daily routines as the percentage of consumers that shop across grocery on DoorDash has continued to grow significantly.” Over 99% of the company’s monthly consumers in the U.S. have access to a non-restaurant retailer via the DoorDash Marketplace , the release said . The new grocery partners include Fresh Encounter , a regional supermarket chain that operates 50 stores under a range of banners in Ohio, Indiana and Northern Kentucky; and Fruitful Yield , a family-owned health food store chain with 11 locations around Chicago. Also on the list are natural/organic grocer Plum Market , based in Michigan and Florida; Robért Fresh Market , a family-owned chain in the Greater New Orleans area; and Stew Leonard’s , a family-owned and operated farm-fresh food store with locations across Connecticut, New Jersey and New York. In related grocery news, Instacart CEO Fidji Simo said last week that the company is focusing on grocery partnerships . Simo has made Instacart’s higher-margin enterprise business a priority, homing in on things like last-mile delivery, creating white-label websites and selling advertising slots on the company app. Instacart has also bolstered its brick-and-mortar offerings, such as electronic shelf tags and smart shopping carts . Simo said she thinks that acting as a technology partner for grocers can help Instacart face off against the likes of Walmart and Amazon as those giants invest in digital grocery tech. “The Amazons and Walmarts of the world might get a fair share of people, but if your favorite retailer of choice is a Publix , a Kroger , an Albertsons , we really are the best place for that,” Simo said.

ORCHARD PARK, N.Y. (AP) — Gratifying as it was for Sean McDermott to catch up with his family and get some rest during Buffalo’s bye week, the Bills coach on Wednesday found comfort returning to his weekly routine and familiar wardrobe — a gray T-shirt and sweatpants. Read this article for free: Already have an account? To continue reading, please subscribe: * ORCHARD PARK, N.Y. (AP) — Gratifying as it was for Sean McDermott to catch up with his family and get some rest during Buffalo’s bye week, the Bills coach on Wednesday found comfort returning to his weekly routine and familiar wardrobe — a gray T-shirt and sweatpants. Read unlimited articles for free today: Already have an account? ORCHARD PARK, N.Y. (AP) — Gratifying as it was for Sean McDermott to catch up with his family and get some rest during Buffalo’s bye week, the Bills coach on Wednesday found comfort returning to his weekly routine and familiar wardrobe — a gray T-shirt and sweatpants. “When I’m not wearing those, I go to my closet and I don’t know what to wear. I’m kind of like not myself,” he said before pulling up his hoodie for emphasis to reveal the gray shirt he had on underneath. “So I was telling some of the guys this morning, ‘It’s good to be back.’” Though there remain challenges ahead, these are upbeat times in Buffalo. The Bills (9-2) are off to their best start since 1992. They remain in contention for the AFC’s top seed by entering their break following a 30-21 win over Kansas City (10-1). And Buffalo is in position to clinch its fifth straight AFC East title as early as Sunday. To do so, the Bills would need Miami to lose to Green Bay on Thursday night, and Buffalo to win its game over San Francisco (5-6) on Sunday night. Buffalo has won six straight since back-to-back losses at Baltimore and Houston, and scored 30 or more points in each of its past five outings. Refreshed as McDermott sounded and appeared, it didn’t take long for him to revert to his game-at-a-time script when assessing what’s on the line this weekend. “We’re mostly focused on our level of play this week against a good football team,” he said. McDermott shed little light on the status of Buffalo’s lengthy list of injured players. There’s no timetable yet on Matt Milano being activated off injured reserve, even though the starting linebacker practiced fully for the first time since tearing his left biceps during a training camp practice in mid-August. Milano has actually missed nearly 14 months since sustaining a season-ending injury to his right leg in Week 5 last season. Milano revealed little during a brief interview following practice. “I feel all right. Getting back into it with the team,” said Milano, who no longer wore a red non-contact jersey in practice. Meantime, rookie receiver Keon Coleman, who has missed two games with a right wrist injury, and starting right tackle Spencer Brown, who missed one game with an ankle injury, were limited in practice. Tight end Dalton Kincaid (knee) was Buffalo’s only player not practicing. Winnipeg Jets Game Days On Winnipeg Jets game days, hockey writers Mike McIntyre and Ken Wiebe send news, notes and quotes from the morning skate, as well as injury updates and lineup decisions. Arrives a few hours prior to puck drop. The Bills also opened the three-week window for backup rookie defensive tackle DeWayne Carter (wrist) and backup offensive lineman Tylan Grable (groin) to return. McDermott has another positive going for him revolving around the bye week. The Bills are 8-0 coming out of their break since McDermott took over as coach in 2017. “I don’t really have the, hey, this is exactly what we do formula,” McDermott said on whether he’s changed his bye week approach. “It’s more of us really just getting back to what we do, getting back to basics.” ___ AP NFL: https://apnews.com/hub/nfl Advertisement Advertisement

An online debate over foreign workers in tech shows tensions in Trump’s political coalition

None

None

Apple has shared the most popular podcasts of 2024 True crime, politics, and interview shows dominate You can view stats for your country in the Podcasts app It's the season to look back on the last 12 months – we're seeing announcements every day now about the apps of the year, the movies of the year, and annual music recaps – and now Apple has published stats on the top podcasts of 2024. The charts cover the most popular shows overall, the most popular new shows, the most popular individual episodes, the most widely shared shows, and the shows with the most subscribers across the year. You can see the results for the results in your own part of the world by opening the Browse tab in the iOS Podcasts app. For the US, the top three shows overall were The Daily news show, the true crime podcast Crime Junkie, and The Joe Rogan Experience interview series. Over in the UK, the podcast charts were topped by The Diary Of A CEO with Steven Bartlett, The Rest Is Politics, and The Rest Is History. When it comes to the best new shows for 2024, the US list was headed by The Tucker Carlson Show, Three (true crime), and Mortal Sin (true crime again). In the UK, the winners were The Rest Is Entertainment, The Rest Is Politics (US version), and Olivia Attwood's So Wrong It's Right – so you can see some of the trends. Top episodes For top episodes in the US, we've got a Crime Junkie episode on the Alphabet murders, Joe Rogan's interview with Donald Trump, and the Daily episode on the Harris vs Trump debate during the US election. In the UK, the top three episodes were claimed by the UK election episode from The Rest Is Politics, the Paul Rudd episode from Off Menu with Ed Game and James Acaster, and the Angela Rayner episode of The Rest Is Politics. Politics, true crime, and interview shows have been dominating the podcast charts in 2024 then – though bear in mind this is based on listening happening through the Apple Podcasts app and not anywhere else (like Spotify, for example). Get the best Black Friday deals direct to your inbox, plus news, reviews, and more. Sign up to be the first to know about unmissable Black Friday deals on top tech, plus get all your favorite TechRadar content. As for the most shared shows we're recommending to friends and family, the top three were Huberman Lab (health), Scamanda (true crime yet again), and Wiser Than Me with Julia Louis-Dreyfus in the US, and Zoe Science & Nutrition, The Rest Is Politics, and The Rest Is History in the UK. You can now stream Apple Podcasts from your web browser Here are our 47 favorite podcasts for your listening pleasure Adventures with Google’s new one-click AI podcast creator

Alberta to fund up $50 million for new drilling test siteDEAR DEIDRE: EVERY time I hug my partner he takes it as an opportunity to grope my boobs or shove a hand up my skirt. I’ve told him I don’t like it – sometimes, he squeezes my breasts so hard that it hurts – but he doesn’t listen. He’s 54, I’m 49 and we’ve been together for five years. He also wants me to talk dirty to him during sex, making me say things I find really disturbing. The sex is very impersonal, and I often feel I’m only there for his pleasure. As soon as it’s over, he ignores me. I think the problem started when he was out of work for a few months and got into the habit of watching online porn and cam girls every day. I kept asking him to stop but he said it was no worse than looking at social media. He tells me that he’s stopped now, but I don’t know if that’s true. Unless he‘s groping me, he ignores me. He blocks out everything I say like it’s white noise. I just get on with doing the housework. I left an abusive marriage ten years ago and I don’t have the strength to end another relationship. I love days when he goes to work because I feel less lonely when he’s not here. DEIDRE SAYS: Nobody is allowed to grope you without your permission. Even though you’re in a relationship, non-consensual touching would still be classified as sexual assault. You might be right that porn has changed how he thinks about sex, as it can create a warped idea of what’s normal. Your first step is to talk to him one last time, and make sure you agree when it is – and isn’t – OK for him to touch you. If he refuses to listen, or won’t acknowledge that he’s overstepped the mark and it shows your feelings don’t matter to him. A lot of his behaviour is abusive, and if things don’t change, you would undoubtedly be happier without him. Having walked away from one abusive man before, it really is understandable that you would need help to go through the upheaval. Please do read my support pack on Abusive Partners. It gives you plenty more advice and resources. Every problem gets a personal reply from one of our trained counsellors. Fill out and submit our easy-to-use and confidential form and the Dear Deidre team will get back to you. You can also send a private message on the DearDeidreOfficial Facebook page or email us at: deardeidre@the-sun.co.uk

Excerpts from recent editorials in the United States and abroad: Dec. 23 The Washington Post on President Biden's commutation of death sentences President Joe Biden’s Monday announcement that he would should not be seen as an act of mercy for people convicted of awful crimes. It was a substantial move to align the United States with the rest of the democratic world, which has largely abandoned the practice of killing people as an instrument of justice. In other words, Mr. Biden’s use of his commutation power was extraordinary — and insufficient. Three men will remain on federal death row, and more people could be put there in future years. Meanwhile, many states continue to execute people. We say this while acknowledging the horrors these people committed; the three men Mr. Biden left on death row were convicted of mass shootings or terrorist attacks. We also acknowledge that a majority of Americans still favors the death penalty, despite a downward trend in recent years. Mr. Biden’s attempt to split the difference, leaving what he considered the worst of the worst on death row, is therefore understandable. Yet the death penalty is expensive, impractical and too often unjustly applied. And, even if the death penalty posed none of these problems, the government should not purposely take lives outside of war or similar conflict. The state should be better — far better — than those who unnecessarily and premeditatedly extinguish human life. Our view has seen substantial wins in recent years. Executions have plummeted as public support for the practice has moderated. But 2024 offered multiple signs that the momentum may be ebbing. President-elect promised . And the Death Penalty Information Center, in its annual end-of-year report, shows that the number of executions nationwide, though still far below their heights at the turn of the century, have been ticking upward in recent years. Twenty-five people were executed in the United States in 2024, slightly up from the previous year and more than twice the reached in 2021. That’s largely the result of efforts by officials in Republican-run states to reactivate the death penalty. Three states this year — Utah, South Carolina and Indiana — carried out their first executions in more than a decade. Alabama also : asphyxiating them with nitrogen gas. The first person subjected to this method, Kenneth Smith, convulsed and gasped for air for four minutes. Following the execution, Alabama Attorney General Steve Marshall to adopt the method. “Alabama has done it, and now so can you,” he said. Increasingly, states are carrying out these executions behind a veil of secrecy. Just last week, Indiana, citing state law, executed Joseph Corcoran with . This year also saw an increase in the number of people sentenced to death, from 21 in 2023 to 26. of those sentences were imposed by nonunanimous juries, thanks to laws in Florida and Alabama that allow jurors to recommend the death sentence even if they don’t reach consensus. In fact, Florida in 2023 allowing death sentences to be imposed if just 8 out of 12 jurors vote in favor. Of course, as Mr. Biden acknowledged in his Monday announcement, most people with death sentences in the United States committed heinous crimes and deserve little sympathy. But one can condemn such acts while also maintaining that executing criminals cannot bring back victims of those crimes or make whole those who lost loved ones. Also, mistakes happen, even in an advanced criminal justice system such as that of the United States. In July, Larry Roberts sentenced to death to be exonerated of his alleged crime since the DPIC starting tracking wrongful convictions in 1973. No one should be comfortable with that number. Since 1976, when the Supreme Court ended its four-year moratorium on the death penalty, more than 1,600 people have been executed in the United States. How many of them were likewise innocent? ONLINE: Dec. 24 The New York Times on the teen mental health crisis Rates of anxiety and depression in adolescents have been . Millions of Americans with mental health problems are not getting the treatment they need for myriad reasons. Many families can’t afford it. And many young people also don’t know where to turn for help. The UJA-Federation of New York, an organization created in 1917 to provide Jewish New Yorkers with economic and social support, is trying to fill the coverage gap for young adults of all backgrounds. The organization helps them get care from its network of mental health professionals through educational outreach at schools, community centers and even coffee shops. This kind of because it has been shown to reach people who might not otherwise seek treatment or support. “Since UJA was founded — and that’s now well over 100 years ago — we have focused on critical issues facing New Yorkers in need,” said Alex Roth-Kahn, a managing director at the organization. That mission has led to decades of supporting people with mental health challenges. Just this year, Marcellus Williams in Missouri for a 1998 murder, even though the prosecuting attorney in St. Louis County filed a motion to vacate his death sentence because DNA testing of the murder weapon ruled him out. And in Texas, a bipartisan group of lawmakers is of Robert Robertson, convicted in the death of his 2-year-old, who prosecutors said died of shaken baby syndrome — though Robertson’s lawyers have cited medical and forensic experts she likely died from undiagnosed pneumonia. Mr. Biden’s intervention this week is a nod to the flaws of the death penalty, but also a need for a system that claims human dignity and equal application of the law as its driving values. State and federal lawmakers should finish the job by abolishing the practice. ONLINE: Dec. 23 The Wall Street Journal on rising life expectancy in the United States Some good news as 2024 nears the end: Life expectancy in the U.S. last year made an unusually sharp increase as deaths from most major causes declined, according to the latest Centers for Disease Control and Prevention report. Americans can expect more longevity gains in the future—as long as Washington doesn’t introduce harmful policies. Life expectancy in 2023 rose 0.9 years to 78.4 while the overall mortality rate adjusted for age declined 6%. Death rates among all age groups fell, and more sharply for middle-aged Americans and seniors. A typical 65-year-old can expect to live another 19.5 years, up from 18.9 years in 2022. The large rebound in a single year owes largely to a decline in Covid deaths as the pandemic receded into the past. Covid deaths last year were roughly the same as those from the flu during a bad flu season. Death rates from cancer, heart disease, diabetes, Alzheimer’s and unintentional injuries (e.g., drug overdoses) also declined. It’s true that U.S. life expectancy is still lower, and deaths from most causes somewhat higher, than before the pandemic when it reached an overall average of 78.8 years. But that’s because of an increase in chronic illnesses, which may have been exacerbated by the pandemic lockdowns. Forced to stay home, many Americans ate and drank more and used more drugs. The Biden Administration claimed credit for the lifespan increase because drug overdoses declined slightly in 2023. Perhaps political attention to the fentanyl scourge is making a difference. But overdoses were still 50% higher last year than in 2019. The truth is that the Administration’s “harm reduction” policies—e.g., distributing sterile needles and opioid-overdose medicine naloxone to addicts—have failed to reduce addiction. A common lament on the political left and right is that the U.S. has a lower life expectancy despite spending more on healthcare than most developed countries. But America also has more chronic disease and drug addiction, which aren’t from failings in private healthcare. Americans have access to more treatments than any country in the world. This is why U.S. cancer survival rates are higher than in most developed countries and continue to improve. Personalized cancer vaccines and CAR T-cell therapies have shown potential to treat deadly cancers like pancreatic and glioblastoma. GLP-1 medicines like Ozempic could help extend lifespans by reducing obesity, diabetes and even drug addictions. The policy risk is that government drug price controls will discourage innovation. Expanding government control over healthcare isn’t the way to make Americans healthier. ONLINE: Dec. 24 The Boston Globe says Republicans taking directions from Elon Musk might want to reconsider Until last week’s budget debacle, Elon Musk was a warm-up act for President-elect Donald Trump. Like the many adulatory openers at Trump rallies and Republican gatherings, he amped up the crowd — but strictly in preparation for the main act. While Democrats like to flash star power at events — A-listers, movie stars, and pop icons — in today’s Republican Party, Trump is the star power. But the rise of Musk as a political figure means that another successful, powerful businessman is potentially poised to eclipse Trump’s voice in the Republican Party, whether he intends to or not. That’s a problem for Trump, who isn’t exactly used to sharing the limelight. The MAGA movement, as Trump allies describe it, is built around the idea that politicians of all stripes are too blinded by corruption, political complications, and self-interest to serve the needs of the American people. Such a movement necessitates an audacious leader who isn’t afraid to break with the pack and stand out — someone exactly like Trump. His no-holds-barred style of leadership has allowed him to quickly overhaul the Republican Party, elevating loyalists and his favored policies with little regard for pushback from liberals or traditional Republicans. Musk, the founder of Tesla and SpaceX, owner of X (formerly Twitter), and the world’s richest man, has been one of Trump’s most important allies in spreading that message. His endorsement, his campaigning efforts, his dollar America PAC, his energizing rally appearances, and even his transformation of X into a “town square” have been vital to spreading Republican messaging. Musk has been a dutiful “First Buddy.” But he could become more than that, as he revealed last week. Starting early Wednesday morning, a mere series of X posts from Musk helped to derail a bipartisan congressional deal to fund the government and avert a shutdown. That Musk had concerns about a 1,500-page budget bill isn’t the issue here; it’s safe to assume that any impenetrable packet of government spending contains eyebrow-raising allocations. What is of concern is how Musk seemingly single-handedly hijacked the process — and how Republicans let him. On X, Musk and his sidekick Vivek Ramaswamy praised Republicans who bowed to his opposition of the bill and put on notice those who didn’t. “Any member of the House or Senate who votes for this outrageous spending bill deserves to be voted out in 2 years!” Musk early Wednesday afternoon, generating more than 47 million views. He beat Trump to the punch — or, maybe, pushed the president-elect into action. Twelve hours after Musk’s first post opposing the bill, JD Vance and Trump a statement condemning the bill. And that evening, Trump on Truth Social that “Any Republican that would be so stupid as to do this should, and will, be primaried.” So Republican leaders dutifully withdrew the bill and replaced it with a slimmed-down alternative that met Musk and Trump’s demands. That bill failed on Thursday. So on Friday, rather than allow the government to shut down, the House voted on and passed a third bill — which looked suspiciously like the initial version with some face-saving changes to placate Musk and Trump — with Democratic votes. That Musk is using his platform to share his views isn’t an issue. As he often points out, he has made X a public square for many different viewpoints — including many of his own detractors. The problem is that Republicans have allowed Musk to disproportionately sway their leadership. That’s not necessarily a problem when Musk is advocating for budget cuts and bureaucratic overhaul in his self-conceived Department of Government Efficiency. DOGE will be an extragovernmental advisory board that might have the potential to help trim some federal fat. In this advisory role, an innovator like Musk, along with his cochair Ramaswamy, have the potential to make helpful recommendations unburdened by the political pressures of being in the federal government. But advisers advise, they don’t direct. Will it be a problem when the new ascendant voice on the right wants to, say, protect his business interests with American adversaries ? He has many potential conflicts of interest in dictating how the American government should spend and not spend its money. His companies Tesla and SpaceX, for example, in government contracts over the past decade. Musk is doing more than swaying policy. He’s also creating a new line of attack for Democrats who are more than pleased to point out that Republicans’ reimagined “working people’s party” is being led by a billionaire puppeteered by a far richer billionaire. On X, Democrats lined up to highlight “President Musk’s” pull, with Senator Chris Murphy about the Trump administration’s “Billionaire First” agenda. Trump is no stranger to criticisms from the left, nor is he particularly stringent about consistency in his policy positions. Like any good populist, Trump has shown himself willing to adapt to his supporters’ whims. He might bristle, however, at the prospect of being relegated to an opening act, a mere figurehead for a party driven by someone younger, richer, and more influential. The bristling may have already started. Trump’s transition spokesperson immediately went on the defense: “President Trump is the leader of the Republican Party. Full stop,” Karoline Leavitt . And maybe some resistance from Team Trump is for the best. Even if Trump agrees with Musk, an unelected billionaire with a long list of conflicts of interest should not have such a direct line of influence over our government. Trump was elected, he should be making the decisions — not waiting for his rich friend to endorse them before Trump himself has even weighed in. Republicans are going to have to answer plenty of tough questions about Musk’s influence on their party over the next four years. None might be as difficult as this: Is Trump willing to let Musk steal his show? ONLINE: Dec. 24 The Philadelphia Inquirer says RFK Jr. cannot be taken seriously as HHS Secretary America’s public health could be at risk if the incoming administration doesn’t correct some of the campaign rhetoric that may have helped Donald Trump win an election but has no merit now that voting is over. For example, inaccurate comments about water fluoridation that prospective U.S. Department of Health and Human Services secretary Robert F. Kennedy Jr. has not taken back. “ , bone fractures, bone cancer, IQ loss, neurodevelopmental disorders, and thyroid disease,” Kennedy said in a November social media post in which he also claimed the president-elect would advise all U.S. water systems to remove fluoride from public water. As is typical with Trump, he has neither embraced nor denied Kennedy’s assertions, preferring to instead suggest support of ideas that he may later reject by nebulously saying of Kennedy: “I’m going to let him go wild on health. I’m going to let him go wild on the food. I’m going to let him go wild on medicines.” Please, don’t. America doesn’t need anyone “wild” in charge of public health. Kennedy can’t be taken seriously when he makes misleading comments about water fluoridation that may have a veneer of truth but don’t hold up when someone takes the time to review the facts. Fluoride is not an industrial waste product. It is a leaches naturally into streams and other water supplies. Its effectiveness in preventing tooth decay was discovered in the 1920s when it was observed that Colorado Springs, Colo., residents whose teeth were stained by excessive fluoride in their water sources had fewer than normal cavities. Kennedy is wrong to suggest the subsequent fluoridation of community water supplies across America occurred hastily and without due investigation of potential dangers. The National Institutes of Health began investigating how fluoride affects the human body in the 1930s, but the first major trial of fluoridation of a community’s water supply didn’t occur until 1945 in Grand Rapids, Mich. President Harry S. Truman signed an act creating the National Institute of Dental Research in 1948 in large part because 20% of young men being drafted for military service were rejected because their teeth were so bad. Meanwhile, 10 years after the Michigan study began, the cavity rate among Grand Rapids children was reduced by more than 60%. Subsequent research shows drinking fluoridated water not only reduces cavities and associated dental pain but correspondingly cuts missed school and work days. Such results prompted cities and towns across America — including Philadelphia — to begin fluoridating their water, so much so that by 2010 the tap water of more than 200 million Americans was flowing from fluoridated systems. There have been virtually zero instances in which putting fluoride in a water system has been blamed for a public health issue since the fluoridation of most of America’s water supplies began. In fact, the Centers for Disease Control and Prevention has ranked water achievements of the 20th century. Kennedy is trying to solve a problem that doesn’t seem to exist. The National Institutes of Health did complete a study that concluded there might be a after long-term exposure to more than twice the federal government’s recommended level of fluoride in drinking water. But why would any town knowingly exceed the government’s fluoridation guidelines by such a large margin? There’s no incentive for local officials to risk their children’s or adults’ health. Kennedy also says fluoridating water systems is no longer necessary. “ when they put it in, but now we have fluoride in toothpaste,” he said. That’s true, fluoride today is in toothpaste, mouthwashes, and other oral hygiene products, but that’s why the recommended level of fluoride in water supplies was reduced from 1.0 parts per million to 0.7 parts per million in 2011. Future research may lead to more reductions in recommended fluoride levels, but there’s no basis for Kennedy’s call for a ban now. Trump’s choice to plot the course of public health agencies that make life-and-death decisions based on scientific evidence is a bad one. Kennedy comes across as someone who loves basking in the limelight too often afforded contrarians who pay little attention to facts. In that same vein, Kennedy has criticized vaccines that have long protected millions of Americans from crippling and deadly diseases. Surely the president-elect can do better with his nominations. ONLINE:Kai Havertz lifts Arsenal to second to show there is life without Saka

No. 25 Illinois 87, Md.-Eastern Shore 40How the Proposed Bathroom Ban on Federal Properties Could Impact Trans FolksUltralight and Light Aircraft Market worth $17.29 billion by 2029, at a CAGR of 11.2%

Smiths Falls police propose 21 per cent budget increase next yearAt the crossroads of news and opinion, ‘Morning Joe’ hosts grapple with aftermath of Trump meetingNo. 2 Ohio State uses dominant 2nd half to run over No. 5 Indiana 38-15

TORONTO — (“ ” or the “ ”), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that it has filed a preliminary prospectus supplement (the “ ”) and intends to file a subsequent prospectus supplement (the “ ”) to its short form base shelf prospectus dated April 7, 2024 (the “ ”) with the securities regulatory authorities in the Provinces of British Columbia, Alberta and Ontario in connection with a commercially reasonable best efforts offering (the “ ”) of common shares of the Company (“ ”). The Offering is expected to be completed on a commercially reasonable best efforts agency basis pursuant to an agency agreement (the “ “) to be entered into between the Company and Bloom Burton Securities Inc. (the “ “), as lead agent and a syndicate of agents (collectively, together with the lead agent, the “ “). The number of Securities to be distributed, the price of each Security and the size of the Offering will be determined by negotiation between the Company and the Lead Agent in the context of the market with final terms to be determined at the time of pricing. It is anticipated the Offering will also include the optional issuance of pre-funded common share purchase warrants (“ ”) of the Company in lieu of Common Shares at the discretion of purchasers of the Offering. Each Pre-Funded Warrant issued in lieu of a Common Share at the election of any purchaser (together with the Common Shares, the “ ”) entitles the holder thereof to acquire one common share (a “ ”) at a nominal exercise price. The Pre-Funded Warrants do not expire. The Company intends to use the net proceeds from the Offering to advance its Phase 2 clinical development of SAT-3247, as well as working capital needs and other general corporate purposes, as set out in the Preliminary Prospectus Supplement. The Offering is expected to close on or about December 20, 2024, or such other date as may be mutually agreed to by the Company and the Lead Agent (the “ “). The Offering is subject to the Company and the Agents entering into a definitive agency agreement, and subject to the satisfaction of customary closing conditions, including the receipt of all necessary regulatory and stock exchange approvals, including approval of the Toronto Stock Exchange (“ ”). In addition, the Securities are anticipated to be offered by way of private placement in certain jurisdictions outside of Canada pursuant to and in compliance with applicable securities laws. For further details with respect to the Offering, please see the Preliminary Prospectus Supplement, a copy of which is available on SEDAR+ at . Access to the Base Shelf Prospectus, the Prospectus Supplement, and any amendments to the documents will be provided in accordance with securities legislation relating to procedures for providing access to a shelf prospectus supplement, a base shelf prospectus and any amendment. The Base Shelf Prospectus is, and the Prospectus Supplement will be (within two business days of the date hereof), accessible on SEDAR+ at . Alternatively, an electronic or paper copy of the Base Shelf Prospectus, the Prospectus Supplement (when filed), and any amendment to the documents may be obtained without charge, from the Lead Agent by email at ,by telephone at [416-640-7585] or by providing the contact with an email address or address, as applicable. The Base Shelf Prospectus and Prospectus Supplement contain important, detailed information about the Company and the proposed Offering. Prospective investors should read the Base Shelf Prospectus and Prospectus Supplement (when filed) before making an investment decision. This press release is not an offer to sell or the solicitation of an offer to buy the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of such jurisdiction. The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “ ”), or any state securities laws, and accordingly, may not be offered or sold to, or for the account or benefit of, persons in the “United States” or “U.S. Persons” (as such terms are defined in Regulation S under the U.S. Securities Act), except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to exemptions therefrom. This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the Company’s securities to, or for the account or benefit of, persons in the United States or U.S. Persons. Satellos is a clinical-stage drug development company dedicated to developing life-improving medicines to treat degenerative muscle diseases. Satellos has invented SAT-3247 as a first-of-its-kind, orally administered small molecule drug designed to restore skeletal muscle regeneration initially in Duchenne muscular dystrophy (DMD). Satellos has generated a significant body of preclinical evidence in DMD to support its discovery that correcting muscle stem cell polarity with SAT-3247 has the potential to restore skeletal muscle regeneration to repair and strengthen muscle that has been damaged. The Company’s lead drug candidate, SAT-3247, is currently in clinical development as a potential disease-modifying treatment for DMD. Additionally, Satellos is leveraging its breakthrough research and proprietary discovery platform MyoReGenXTM, to identify degenerative muscle diseases where deficits in muscle regeneration occur that are amenable to therapeutic intervention for future clinical development. For more information, visit . This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding Satellos and its business, which may include, but are not limited to, statements with respect to the anticipated terms and jurisdictions of the Offering; securities offered thereunder; the timing of the Offering, including the anticipated Closing Date; use of proceeds from the Offering; inclusion of additional agents; fees anticipated to be paid to the Agent and terms thereof; regulatory and exchange approvals, including the listing of the common shares offered pursuant to the Offering on the TSX; general benefits of modulating stem cell polarity; its prospective impact on Duchenne patients and muscle regeneration generally; and Satellos’ technologies and drug development plans. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking information or statements”. Often but not always, forward-looking information or statements can be identified by the use of words such as “shall”, “intends”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate” “anticipate” or any variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “might”, “can”, “could”, “would” or “will” be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, those listed in the “Risk Factors” section of the Preliminary Prospectus Supplement and the Annual Information Form dated March 26, 2024 (both of which are on the Company’s profile at ). Although Satellos has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Satellos does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. Liz Williams, CFO, Jessica Yingling, Ph.D., , +1.858.344.8091Duke vs. Arizona prediction: College basketball picks, odds, best bets Friday